Argos fully enrolls its trial to test a cancer therapy

Argos is developing a therapy to treat metastatic renal cell carcinoma (mRCC) and hit the enrollment goal of 450 randomized patients. This is a Phase 3 trial, meaning it is one of the last major steps a drug developer takes before submitting an application with the U.S. Food and Drug Administration.07/16/2015
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news